7,870 Shares in BioNTech SE (NASDAQ:BNTX) Bought by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC purchased a new position in BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 7,870 shares of the company’s stock, valued at approximately $831,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BNTX. Baillie Gifford & Co. increased its holdings in BioNTech by 15.5% in the 3rd quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock worth $934,612,000 after acquiring an additional 1,152,541 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in BioNTech by 4,861.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 972,535 shares of the company’s stock worth $1,531,000 after acquiring an additional 952,932 shares in the last quarter. BlackRock Inc. increased its holdings in BioNTech by 25.9% in the 1st quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock worth $274,768,000 after acquiring an additional 331,101 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in BioNTech during the 1st quarter worth $42,711,000. Finally, Point72 Asset Management L.P. boosted its stake in BioNTech by 175.1% during the 4th quarter. Point72 Asset Management L.P. now owns 302,600 shares of the company’s stock worth $45,457,000 after purchasing an additional 192,600 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 0.6 %

Shares of BNTX stock opened at $86.48 on Monday. The company’s 50-day moving average price is $91.97 and its 200-day moving average price is $97.90. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. The stock has a market cap of $20.56 billion, a price-to-earnings ratio of 20.99 and a beta of 0.23. BioNTech SE has a twelve month low of $85.21 and a twelve month high of $131.52.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a net margin of 24.26% and a return on equity of 4.60%. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. As a group, equities analysts predict that BioNTech SE will post -1.67 earnings per share for the current year.

Wall Street Analyst Weigh In

BNTX has been the topic of several recent research reports. The Goldman Sachs Group lowered their target price on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 28th. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research note on Friday, March 22nd. Oppenheimer initiated coverage on shares of BioNTech in a research note on Friday, January 5th. They set a “market perform” rating on the stock. BMO Capital Markets lowered their target price on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating on the stock in a research note on Thursday, March 21st. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 target price on shares of BioNTech in a research note on Thursday, March 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $120.40.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.